| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55b3c57786dd530faffde4e75dcf65ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ba8683fa6cc002524054b548eb2498e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d083c16e95aaee16bfc2ccf9f47d58e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_245f26a06d71d241910e5c195b2ad806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1de3cb28edc9d7e343482252f2f2e5e7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate |
2005-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53a486485396ba4326e2b58a81092cbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d25e4ca8037ea9b9cea9d2363f2106af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f83fc6e9f2e7f865fb2565f71b7962c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10f0a1e0e8a40f4b2e26654599dc30a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc85f4575be61909764863a3ec6340de |
| publicationDate |
2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008051447-A1 |
| titleOfInvention |
Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors |
| abstract |
The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015155060-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022216953-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2929785-A1 |
| priorityDate |
2005-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |